Physician profile
Brian J Downs
NPI 1881795631
$834.52
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $465 · 2020: $65.19 · 2021: $243 · 2022: $61.49.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $261.51 | 2019-2022 | |
| Osiris Therapeutics INC. | $113.08 | 2019 | |
| Organogenesis INC. | $72.08 | 2019 | |
| Biotissue Holdings INC. | $71.86 | 2021-2022 | |
| Gilead Sciences, INC. | $70.38 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $52.13 | 2019-2020 | |
| Tactile Systems Technology INC | $38.48 | 2019 | |
| Kci USA, INC. | $27.95 | 2019-2021 | |
| Misonix INC | $23.97 | 2019 | |
| Tei Medical INC. | $23.54 | 2019 | |
| Genentech USA, INC. | $18.37 | 2020 | |
| Medline Industries Lp | $17.73 | 2019 | |
| Pfizer INC. | $15.11 | 2019 | |
| Hartmann USA, INC. | $14.94 | 2021 | |
| Integra Lifesciences Corporation | $13.39 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Downs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.